M Früh
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U, Soo R, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J, de Castro J, Coate L, Früh M, Hashemi S, Nadal E, Carcereny E, Sala M, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:100507.
Jun 10, 2022Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Jun 10, 2022ESMO Open 2022; 7:100507
Dafni U, Soo R A, Peters S, Tsourti Zoi, Zygoura P, Vervita K, Han J-Y, de Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli G, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO Open 2022; 7:100446.
Apr 12, 2022Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Apr 12, 2022ESMO Open 2022; 7:100446
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali PA, Ceresoli G L, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open 2022; 7:100455.
Apr 7, 2022Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
Apr 7, 2022ESMO Open 2022; 7:100455
König D P, Scharl Sylvie, Vuong D, Guckenberger M, Furrer Katarzyna, Opitz Isabella, Weder W, Rothschild S I, Ochsenbein A, Zippelius A, Addeo Alfredo, Mark M, Eboulet E I, Hayoz S, Thierstein S, Betticher D C, Ris H-B, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021; 33:181-192.
Nov 26, 2021A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Nov 26, 2021Ann Oncol 2021; 33:181-192
Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2014; 87:85-7.
Nov 18, 2014Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Nov 18, 2014Lung Cancer 2014; 87:85-7
Schmid S, Siano Marco, Joerger M, Rodriguez Regulo, Müller J, Früh M
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi99-105.
Jun 27, 2013Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jun 27, 2013Ann Oncol 2013; 24 Suppl 6:vi99-105
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group